CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that Dr. Peter Mueller, Vertex’s Executive Vice President, Drug Innovation and Realization and Chief Scientific Officer, will expand his leadership responsibilities to cover all of Vertex’s global research and development, including clinical and non-clinical development, clinical operations, medical and regulatory affairs as of May 15, 2009 upon Freda Lewis-Hall’s departure. In this new role, Dr. Mueller will become Vertex’s Executive Vice President, Global Research and Development and Chief Scientific Officer.
